Shares of Sareum Holdings plc (LON:SAR – Get Free Report) shot up 27.6% during mid-day trading on Tuesday . The company traded as high as GBX 38 and last traded at GBX 37. 2,280,295 shares traded hands during trading, an increase of 849% from the average session volume of 240,317 shares. The stock had previously closed at GBX 29.
Sareum Stock Performance
The company’s 50 day moving average price is GBX 23.98 and its 200-day moving average price is GBX 20.50. The stock has a market cap of £50.45 million, a P/E ratio of -9.34 and a beta of -1.08.
Sareum Company Profile
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Recommended Stories
- Five stocks we like better than Sareum
- Is Quantinuum Emerging as a Leader in the Quantum Race?
- J.M. Smucker’s Rally Nears a Key Test: Is a Full Recovery Ahead?
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
